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Superficial tumours are the most frequent presentation of transi-
tional cell carcinoma of the bladder (SBTCC) (Pansadoro et al,
1995; Rosenbaum et al, 1996). These tumours demonstrate a
higher tendency to recur either at the same stage and grade or as
deeply invasive tumours after initial surgical resection (Hurle et al,
1996; Lamm and Torti, 1996; Esrig et al, 1997). This biological
behaviour constitutes a common clinical dilemma as far as an
optimal management and points to the need for an effective
prophylactic treatment of these tumours (Carballido et al, 1990a;
Kurth, 1997; Kurth et al, 1997; Molt￿ et al, 1997; Witjes, 1997)
after their transurethral resection of the tumor (Patard et al, 1993;
Molto et al, 1995).
Interestingly, several alterations have been described in the
immune system of patients with SBTCC. These alterations include
the functional impairment of T-lymphocytes and NK cells, whose
intensity appears to be related to the progression of the disease
(Carballido et al, 1990a; 1990b; Jackson et al, 1994).
Intravesical instillation of several immunomodulators, such as
bacillus Calmette—Gu￿rin (BCG), has been proposed as prophyl-
actic adjuvant therapy (Erton et al, 1996; Kurth, 1997b; Witjes,
1997). The mechanism of action of intracavitary instillations with
BCG remains partially known. A potential direct effect of BCG
against tumour cells inhibiting their proliferation and inducing
their differentiation has been proposed (Patard et al, 1993; Jackson
et al, 1994; Akaza et al, 1995). There is also evidence that intra-
cavitary BCG instillations induce a strong infiltration of inflam-
matory cells including activated immune cells in the bladder wall
(Maes et al, 1995; Erton et al, 1996). The characteristics of this
immune response appears to be related to the clinical outcome of
the patients (Ratliff et al, 1993; Zlotta et al, 1994; Maes et al, 1995;
De Reijke et al, 1996; Turner and Dockrell, 1996; Molt￿ et al,
1997). The immunoregulatory effects of intracavitary BCG
instillations in SBTCC patients may play a relevant role in its
anti-tumour effect.
Heterogeneous clinical response to intracavitary BCG instilla-
tions in SBTCC patients have been described (Nadler et al, 1994;
Mack and Frick, 1995; O￿Donnell and DeWolf, 1995; Takashi et al,
1995). There is evidence that around 30% of treated patients show
recurrence of the disease (Nadler et al, 1994; Lapham et al, 1997).
It has been shown that the patient￿s immune system status may
determine the response to the treatment with immunomodulators
(Hermann et al, 1990; Verhagen et al, 1990; Molt￿ et al, 1997). It is
possible that the phenotypical and functional characteristics of the
immune system of untreated SBTCC patients after transurethral
resection of the tumour may have a prognostic tool for the identifi-
cation of the clinical response to prophylactic use of BCG.
We have investigated the potential existence of differences in
the distribution of T-lymphocyte subsets and in the proliferative
response of these CD2+ cells to polyclonal mitogens in patients with
SBTCC treated with prophylactic intracavitary instillations with
BCG, in accordance with their clinical response to this treatment.
In those patients who remained free of recurrence of the disease
after 1 year of follow-up, we also studied the effects of intracavitary
instillations with BCG in these immunological parameters.
MATERIALS AND METHODS
Patients
Eighteen patients with histologically proven transitional cell
bladder carcinoma were included in this study (Table 1). The
degree of tumour invasion was classified according to the tumor
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nodes and metastasis staging system (TNM) adapted by the
International Union Against Cancer, and grade according to Koss
(1973). All the patients entered in the study had superficial
tumours (stages Ta and T1 and grades 1 to 3). The tumours were
completely resected with the muscle layer in each case and
random multiple biopsies were taken. None of the patients had
received any treatment within the 6 months prior to the study, nor
had they any other disease which could affect the immune system.
Twenty healthy male control subjects (median 60 years and range
43—76) were selected for the study. All patients were studied prior
to transurethral resection of the tumour and 3, 6 and 12 months
after beginning a treatment according to the following protocol: 6
weekly intracavitary instillations of 81 mg of BCG (ImmuCyst,
Connaught, Toronto, Canada). Five patients had recurrence during
this follow-up period (median of recurrence time: 7 months, range
3—8) and had included in others protocols. Blood samples were
obtained before the surgery and anaesthetic procedures and
informed patient consent was secured for the study.
Cell separation
Peripheral blood mononuclear cells were obtained by
Ficoll—Hypaque (Lymphoprep Nyegaard and Co., Oslo, Norway)
gradient (Boyum, 1968). T-cells were purified by rosetting with
sheep red blood cells pretreated with 2-aminoiethylisothio-
uronium bromide, as previously described (Madsen et al, 1980).
After counting, cells were resuspended in RPMI-1640 (Whitaker
Bioproducts, Walkersville, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Biochrom KG, Berlin), L-glut-
amine (2 mM Biochrom KG, Berlin), Hepes (25 mM Biochrom),
and 1% penicillin—streptomycin (Difco Lab, Detroit, MI, USA);
this will be referred to as complete medium. Cell viability checked
by trypan blue exclusion was always greater than 95%. The purity
of phenotypically defined CD2+ lymphocytes in the rosette
cellular preparations was higher than 85% in all cases. Cellular
cultures were performed at 37°C in a humidified atmosphere
containing 5% carbon dioxide.
Staining of cells and flow cytometry analysis
Immunofluorescence studies were performed on fresh purified
CD2+ lymphocyte preparations. In the dual-colour experiments,
fluorescein isothiocyanate (FITC)- and expression of phycoerythrin
(PE)-labelled MAbs against membrane antigens was analysed. The
MAbs used in this study were anti-CD2 (T and NK cells), anti-
CD56 (NK cells), anti-CD19 (B cells), anti-CD16 (NK cells), anti-
CD4 (helper/inducer cells), anti-CD8 (cytotoxic/suppressor cells),
anti-CD25 (a-chain of IL-2 receptor), anti-HLA-DR DR (MHC
class II molecules), anti-CD71 (transferrin receptor), anti-CD45
(pan human leucocyte) and anti-CD14 (macrophages, neutrophils).
Furthermore, the MAb anti-CD3 (T cells) was used as a third colour
(PerCP). Control studies with unstained cells and cells incubated
with isotype-matched irrelevant FITC-, PE- and PerCP-labelled
MAbs were performed for each experiment. All MAbs were
obtained from Becton and Dickinson (Mountain View, CA, USA).
Acquisition and tricolour immunofluorescence analysis was
performed with a FACScan flow cytometer and Lysis II software
(Becton Dickinson). For leucocyte immunological study, a bipara-
metric electronic gate was drawn around CD45 + CD14— cells.
Proliferation studies
Fresh CD2+ lymphocytes (50 000 cells per well) were cultured in
complete medium on 96 flat-bottom culture plates in the presence
of different mitogens for 3, 5 and 7 days. The mitogenic stimuli
analysed included phytohaemagglutinin (PHA, 10 mg ml—1, Difco)
in the presence or absence of recombinant human interleukin 2
(rhIL-2, 100 IU ml—1, Hoffman-La Roche, Nutley, NJ, USA),
plastic-immobilized anti-OKT3 (anti-CD3, 5 mgm l —1, Ortho-mune,
Orthodiagnostic System) and O-tetredecanoylphorbol 13-acetate
(TPA, 10 ng ml—1, Sigma, St Louis, MO, USA). DNA synthesis was
measured during the last 18 h of the culture period by incubation of
1 mCi of [3H]thymidine (Radiochemical Center, Amersham, UK).
Statistical analysis
Comparison of the measures for the immune phenotype and prolif-
eration median values between patients with or without recurrence
and healthy controls were tested with the Mann—Whitney U-test.
Differences in the same parameters in the SBTCC patient group
who were free of tumour recurrence at the different times of
follow-up were assessed with two related samples: a non-para-
metric test for repeated measurements. P-values were considered
significant when less than 0.05. Analysis of data was done using
SPSS for Windows (Release 6.0).
RESULTS
Different subset distribution and activation antigen
expression were found in CD2+ cells from SBTCC
patients prophylactically treated with BCG who
remained free of disease or those who had recurrence
of tumour
The potential existence of differences in the lymphocyte subset
distribution and activation antigen expression of purified CD2+
cells from a group of 18 SBTCC patients before the prophylactic
intracavitary instillations with BCG and healthy control subjects
(n = 20) were analysed (Table 2). The SBTCC patients were
classified according to their clinical performance after the intra-
cavitary BCG treatment (13 patients remained without clinical and
pathological evidence of tumour recurrence and five patients with
recurrence introduced into other adjuvant protocols). The expres-
sion of the cell-surface antigens CD3, CD4, CD8, CD16, CD56
Table 1 Patient and tumour characteristicsa
Age (years) 64 (41–82)
Sex 18 Male: 0 Female
Number of tumours
Single 12
Multiple 6
Size
≤2c m 4
>2 cm 14
Stage
Ta (multiple) 2
T1 16
Grade
10
27
31 1
aAll tumours were primary. Associated carcinoma in situ excluded.1164 E Reyes et al
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and CD19 as well as activation antigens CD25, CD71 and HLA-
DR was analysed in the purified CD2+ lymphocyte preparations
from both groups of patients and healthy control subjects. There
were no significant differences in the percentages of CD2+
lymphocyte purification obtained in the cellular preparations from
the different groups of patients. There were no significant differ-
ences in the level of CD3+ lymphocytes and CD16+ NK cells
present in the purified CD2+ fractions from both groups of
SBTCC patients and healthy control subjects. However, the
percentage of CD3+CD56+ cytotoxic T-lymphocytes was signifi-
cantly higher in the CD2+ preparations from patients with recur-
rence of disease than in those found in patients who remained free
of disease and healthy control subjects (Table 2).
There were no significant differences in the percentages of CD4
T-lymphocytes found in the CD2+ cells from both groups of
patients and healthy controls (Table 2). However, the percentages
of CD8+ lymphocytes in CD2+ preparations from patients with
tumour recurrences were marginally but significantly higher than
those found in patients who remained free of disease and healthy
controls. The CD4/CD8 ratio was significantly lower in patients
with tumour recurrences than that found in patients who remained
free of disease and healthy controls.
The expression of CD25 antigen by CD2+ cells from healthy
donors was lower than that in both groups of patients; however, no
differences were observed between patient groups. In contrast,
the expression of other activation antigens, namely CD71 and
HLA-DR, was significantly higher in patients without recurrence
compared with patients who relapsed or with healthy controls.
Different proliferative response to mitogenic signals is
found in CD2+ cells from SBTCC patients
prophylactically treated with BCG who remained free of
disease or those who had tumour recurrence
The proliferative response of CD2+ cells from the described
SBTCC patients and healthy controls to polyclonal mitogens
(PHA, anti-CD3 and TPA) in the presence or absence of rhIL-2
were analysed. In kinetic studies performed at 3, 5 and 7 days of
culture, the maximal proliferative response to PHA of purified
CD2+ preparations from patients and controls was found at 5 days
of culture (data not shown). The proliferative response of CD2+
cells from patients with tumour recurrence to PHA stimulation in
the presence or absence of exogenous rhIL-2 was significantly
lower than that found in patients who remained free of disease
(Figure 1). The proliferative response of CD2+ cells from both
groups of SBTCC patients to rhIL-2 or PHA or PHA plus IL-2 was
significantly decreased with respect to that found in healthy
control subjects. There were no significant differences in the
proliferative response of CD2+ cells in both groups of patients to
the stimulation with anti-CD3 or TPA (Figure 1).
The prophylactic intracavitary BCG instillations in
SBTCC patients are associated with a transitory
T-lymphocyte subset distribution and activation
antigens expression
The potential existence of modifications in the distribution of the
lymphocyte subsets in the CD2+ cell preparations from the
SBTCC patients that completed the 12 months of follow-up
(13 patients then remained free of tumour recurrence) after begin-
ning of the intracavitary BCG instillations was analysed (Table 3).
At four different timepoints analysed during the 12 months of
follow-up, there were no significant differences in the percentages
of cells that expressed the CD2, CD3, CD16, CD56 or CD19 anti-
gens in the purified CD2+ preparations from this group of SBTCC
patients. However, the percentage of CD4 T-lymphocytes in CD2+
preparations increased significantly at 3 and 6 months after the
beginning of the intracavitary BCG instillations with respect to the
values observed before this treatment. A concomitant decrease
in the percentage of CD8+ lymphocytes and increase in the
CD4/CD8 ratio in those cellular preparations was observed. At
12 months of follow-up, these significant differences in the distri-
bution of the CD4+ and CD8+ lymphocyte subsets in CD2+ prepa-
rations from the intracavitary BCG-treated patients disappeared,
contrasting with those observed before this treatment.
The percentage expression of the activation antigen CD25 by
CD2+ cells from these SBTCC patients also significantly
increased after 6 months follow-up compared with that observed
Table 2 Lymphocyte subpopulations and activation antigen expression before BCG treatment in patients
who had no recurrence at the end of the study; those with relapse and healthy controls
SBTCC patients
Tumour recurrence Free of tumour recurrence Healthy controls
MAb (n = 5) (n = 13) (n = 20)
CD2+ 88.2 ±3.0 90.9 ± 5.9 92.8 ± 3.2
CD3+ 72.2 ± 1.8 78.8 ± 3.5 76.9 ± 1.6
CD4+ 32.6 ± 7.5 39.5 ± 3.4 44.1 ± 2.0
CD8+ 41.0 ± 4.5a,b 37.3 ± 2.9 37.2 ± 2.1
CD4/CD8 0.9 ± 0.2a 1.2 ± 0.1 1.3 ± 0.6
CD16+ 21.8 ± 6.4 19.4 ± 10.6 16.6 ± 8.9
CD56+ 29.4 ± 8.7 24.4 ± 11.6 23.2 ± 10.7
CD3+CD56+ 16.5 ± 7.7a,b 8.3 ± 1.8 8.9 ± 1.4
CD19+ 2.7 ± 1.2 3.7 ± 3.4 2.8 ± 0.7
CD25+ 11.3 ± 0.9a 17.3 ± 4.9a 8.0 ± 1.1
CD71+ 2.7 ± 1.8a,b 7.6 ± 3.2a 3.8 ± 0.8
CD3+HLADR+ 5.6 ± 1.0b 12.4 ± 4.8a 5.7 ± 0.7
The values are expressed as means of percentage ± s.d. aP<0.05 vs. controls. bP<0.05 vs. patients with no
recurrence.Relapse of bladder cancer and CD2+ cells abnormalities 1165
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after 3 months of the beginning of the intracavitary treatment
(Table 3). There were no significant differences in the expression
of CD71 antigen and HLA-DR molecules by these CD2+ cells at
different times analysed throughout the study.
The proliferative response of CD2+ cells from these prophyl-
actic intracavitary BCG-treated SBTCC patients to PHA, anti-
CD3 antibodies and TPA during the 12 months of follow-up was
analysed. In these patients, as well as in the healthy controls
studied in parallel, we did not observe significant modifications
in the expression of the antigens analysed in CD2+ cells or in their
proliferative response to the polyclonal mitogens (data not
shown).
DISCUSSION
The mechanism of action of the intracavitary prophylactic instilla-
tions with BCG after transurethral resection of the tumour has yet
to be established (Patard et al, 1993; O￿Donnell and DeWolf,
1995). It is known that the effect of the biological response modi-
fiers in the treatment of tumour patients are related to the patient￿s
immune status. Although the patient groups included in this pilot
study are small, our data suggest that those who remained free of
tumour recurrence at 1 year follow-up after the initiation of the
intracavitary instillations with BCG showed different phenotypic
and functional characteristics in their purified CD2+ cells
compared with those showing clinical and pathological evidence
of tumour recurrence during the time of analysis. It is important to
note that the tumour recurrence patients were included in different
therapy protocols. For this reason, similar analysis could not be
found in the non-responsive patient population.
An enhancement in the percentage of CD8 and CD56 T-
lymphocytes in CD2+ cells before the BCG treatment was
observed in patients with recurrence of the tumour when compared
with those patients who remained free of disease. It is known
that these T-lymphocyte subsets have been associated to
suppressor/cytotoxic activities (Walker et al, 1995; Turner and
Dockrell, 1996). Interestingly, it has been described that in the
presence of IL-2 and IL-12, the CD3+CD56+ lymphocytes
increase their cytotoxic activity and for this reason they may play
an important positive role in the anti-tumour response of the
patient￿s immune system (Satoh et al, 1996). This apparent contra-
diction might be related to a potential primary or secondary
functional impairment of these effector cells and/or to a lack of
sensitivity of the recurrent tumour cells to their lytic activity. It is
also important to emphasize that the percentage of CD8 lympho-
cytes found in CD2+ cells from patients before BCG treatment
who suffered recurrence of the disease during the follow-up was
marginally but significantly higher than that found in healthy
controls. This phenotypical abnormality found in CD2+ cells from
patients with recurrence of the tumour is also associated with a
significantly decreased proliferative response to polyclonal mito-
genic stimulation with PHA. This blastogenic response to PHA is
dependent on in vivo T-cell activation (HLA-DR expression)
rhIL-2
PHA
PHA+rhIL-2
anti-CD3
TPA
Free of disease Recurrence tumour Healthy controls
SBTCC patients
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Figure 1 Proliferative response to PHA, IL-2, PHA plus IL-2, anti-CD3 and
TPA of CD2+ cells purified from peripheral blood before BCG treatment of the
SBTCC patients (5 and 13 in the recurrence/no recurrence groups)
respectively and healthy controls (n = 20). Cells, 50 000 per well were
cultured in complete medium in the presence of different mitogens. Cultures
were incubated at 37°C in a humidified atmosphere containing 5% carbon
dioxide for 5 days. DNA synthesis was measured during the last 18 h of the
culture period by incubation of 1 mCi [3H]thymidine. Boxes represent the
interquartile range (percentile 25 to percentile 75) of each group and the lines
dividing the boxes represent the median in counts per minute (c.p.m.) of each
group. Error bars represent percentile 5 and 95 respectively. *P<0.05 vs.
SBTCC patients with recurrence tumour. †P<0.05 vs. healthy controls
Table 3 Lymphocyte populations and expression of activation antigens in CD2+ cells purified from peripheral
blood of SBTCC patients free of tumour recurrence at different times of follow-up
SBTCC patients
(n = 13)
MAb Basal 3 months 6 months 12 months
CD2+ 90.9 ± 5.9 90.7 ± 5.1 96.5 ± 4.0 93.1 ± 5.0
CD3+ 78.8 ± 3.5 74.1 ± 11.3 81.6 ± 4.9 76.3 ± 5.3
CD4+ 39.5 ± 3.4 51.2 ± 5.0a 56.1 ± 2.3a 49.7 ± 6.7
CD8+ 37.3 ± 2.9 24.6 ± 3.2a 26.8 ± 5.3a 33.3 ± 5.3
CD4/CD8 1.2 ± 0.1 2.0 ± 0.9a 2.1 ± 0.7a 1.5 ± 0.6
CD16+ 19.4 ± 10.6 10.4 ± 2.3 11.8 ± 3.0 11.9 ± 2.3
CD56+ 24.4 ± 11.6 18.8 ± 6.1 20.7 ± 5.0 24.3 ± 5.3
CD3+CD56+ 8.3 ± 1.8 3.8 ± 0.9 6.3 ± 0.7 6.4 ± 1.0
CD19+ 3.7 ± 3.4 5.3 ± 2.6 5.3 ± 3.7 2.4 ± 2.5
CD25+ 17.3 ± 4.9 14.3 ± 3.6 22.6 ± 9.1b 13.7 ± 6.3
CD71+ 7.6 ± 3.2 6.6 ± 2.1 7.0 ± 1.6 2.6 ± 0.4
CD3+HLADR+ 12.4 ± 4.8 11.2 ± 2.4 13.1 ± 4.7 9.8 ± 2.7
The values are expressed as means of percentage ± S.D. aP<0.05 vs. basal determination. bP<0.05 vs.
determination at 3 and 12 months.1166 E Reyes et al
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(Turner and Dockrell, 1996) and on the use of the IL-2 regulatory
pathways by them (Larson et al, 1980). It has been shown that
CD8 lymphocytes may suppress the proliferative response of the
whole population of T lymphocytes to IL-2 (Nicks et al, 1990). It
is important to note that the defective proliferative response of
CD2+ cells from patients with later recurrence of the disease to
PHA is not reversed by exogenous IL-2. This severe defective
proliferative response of CD2+ cells to PHA stimuli found in
subjects with recurrence of the tumour, agrees with the observed
clinical prognostic value of the induction of IL-2 messenger RNA
on peripheral blood mononuclear cells from SBTCC patients
treated with prophylactic intravesical BCG instillations (Kaempfer
et al, 1996). The potential relevance of the IL-2 pathway in the
response to BCG in these patients might also be suggested by the
increased expression of the a-chain of the IL-2 receptor observed
in CD2+ cells from patients that remain free of tumour recurrence
after this prophylactic treatment.
Interestingly, before starting the intracavitary BCG instillations,
CD2+ lymphocytes from patients who remained free of tumour
recurrence during 12 months of follow-up showed a significant
increased percentage of cells that expressed CD71 activation
antigen and DR molecules with respect to those observed in
patients with recurrence of the disease. It is known that the pres-
ence of tumour cells induce a response in the host￿s immune
system. In this sense, CD2+ cells from both groups of patients
have a clear percentage increase of activated T lymphocytes with
respect to that found in healthy controls. Taken together, these
results suggest that the existence of an in vivo activation of the
CD2+ cells may act as a preconditional factor responsible for the
clinical effectiveness of BCG. According to the data from this
study, phenotypic and functional characteristics of CD2+ cells
from patients with SBTCC are associated with different clinical
responses to the prophylactic intracavitary BCG treatment. These
results agree with previous findings in animal models that confirm
the pivotal role of T lymphocytes and NK cells in BCG-mediated
anti-tumour activity (Carballido et al, 1990b; Pryor et al, 1995;
Thanhauser et al, 1995; Turner and Dockrell, 1996).
There is evidence that intravesical BCG induces a strong
immune response in the bladder wall (Maes et al, 1995; De Reijke
et al, 1996). Infiltration of activated CD4+ and CD8+ T lympho-
cytes and macrophages in the bladder wall appears to be related to
the therapeutic activity of BCG (Pryor et al, 1995). The immune
system is a complex cellular and molecular net with multiple and
continuous functional interaction among its elements. Furthermore,
there is also a continuous traffic of immune cells between organs
and peripheral blood (Picker et al, 1990). In agreement with this
physiological concept of the immune system, it has been shown
that organ-localized inflammatory autoimmune diseases are associ-
ated with systemic immune system abnormalities (Maes et al,
1995). Accordingly, we have investigated the potential systemic
effects of intracavitary instillations with BCG on the CD2+ cells of
SBTCC patients. We have observed that the intracavitary instilla-
tions with BCG induce a significant enhancement in the percentage
of the CD4+ T lymphocytes with a concomitant significant
decrease in the CD8+ subsets. In addition, an increase in the
expression of the CD25 lymphocytes by these CD2+ cells is also
observed. These effects are observed at 3 and 6 months after the
initiation of the six weekly instillations of BCG. The existence of
these systemic modulatory effects of the intracavitary instillations
with BCG agree with previous observations of functional effects of
cytokine production by peripheral blood monocytes associated with
this treatment (Jackson et al, 1995; Pryor et al, 1995). These
systemic effects uphold the claim of functional lymphocyte interac-
tions between peripheral blood lymphocytes and those involved in
the local inflammatory bladder wall response (Prescott et al, 1992;
Erton et al, 1996). A traffic of these bladder wall lymphocytes to
peripheral blood may also be involved.
We have not observed that the defective proliferative response
of CD2+ cells to polyclonal mitogens found before BCG treatment
in those patients who remained free of disease would be normal-
ized by this immunomodulatory treatment. This finding might
suggest that modifications in the schedule of BCG treatment
and/or association with other immunomodulatory agents may
more effectively regulate the host￿s immune system and improve
clinical results. Furthermore, the limited duration of the
immunomodulator effect of intracavitary instillations with BCG
indicates that the cyclic use of these bacteriological preparations
might maintain the effect and improve therapeutic results of
prophylactic use of intracavitary BCG in patients with SBTCC.
The small number of patients included in this study limits the
power of statistical test. Significance tests are being used to indi-
cate particular areas that are identified for further investigation.
Additional studies are required in order to define the clinical
significance of the initial immune status of patients with SBTCC
found in this pilot study. A prophylactic use of intracavitary instil-
lations with BCG in patients with higher chance of positive
response to this treatment might improve the clinical outcome.
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